Products Ocriplasmin is commercially available as an injectable (Jetrea). It has been approved in many countries since 2014. Structure and properties Ocriplasmin is a recombinant and truncated derivative of the human proteolytic enzyme plasmin with a molecular weight of 27.2 kDa. It is produced by biotechnological methods. Effects Ocriplasmin (ATC S01XA22) has proteolytic properties on … Ocriplasmin
Products Pegaptanib was commercially available as a solution for injection (Macugen). It was approved in many countries in 2006 and has since been discontinued. Structure and properties Pegaptanib is an aptamer and a pegylated and modified oligonucleotide. Effects Pegaptanib (ATC S01LA03) binds to extracellular vascular endothelial growth factor (VEGF) and inhibits its activity. VEGF plays … Pegaptanib
Products Brolucizumab was approved as a solution for injection in the United States in 2019 and in many countries in 2020 (Beovu). Structure and properties Brolucizumab is a humanized monoclonal antibody fragment with a single Fv chain (single-chain antibody fragment, scFv). The molecular mass is in the range of 26 kDa. It is significantly lower … Brolucizumab
Products Voretigenneparvovec was approved in the United States in 2017, in the EU in 2018, and in many countries in 2020 as a concentrate and solvent for the preparation of a solution for injection (Luxturna). Structure and properties Voretigenneparvovec is the capsid of an adeno-associated viral vector serotype 2 (AAV2). It contains the cDNA of … Voretigenneparvovec
Products VEGF inhibitors are commercially available as injectables from various suppliers. The first agent in this group to be approved was pegaptanib (Macugen) in 2004, which is now off the market in many countries. Structure and properties The currently available VEGF inhibitors are therapeutic proteins (biologics). They are antibodies, antibody fragments, and fusion proteins. They … VEGF Inhibitors
Products Aflibercept is marketed as an injectable (Eylea). It was approved in many countries in 2012. Structure and properties Aflibercept (C4318H6788N1164O1304S32) is a recombinant fusion protein consisting of the extracellular portions of human VEGF receptor 1 and 2 coupled to the Fc receptor of human IgG1. Effects Aflibercept (ATC S01LA05) binds the growth factors VEGF-A … Aflibercept
